79200-57-0

Basic information

• Product Name: (1R,2S,3R,4R)-2,3-DIHYDROXY-4-(HYDROXYMETHYL)-1-AMINOCYCLOPENTANE HYDROCHLORIDE
• Synonyms: (1R,2S,3R,4R)-2,3-DIHYDROXY-4-(HYDROXYMETHYL)-1-AMINOCYCLOPENTANE HYDROCHLORIDE;(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)-1-aminocyclopentaneHCl,(ee);(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)-1-aminocyclopentanehydrochloride,(ee);(1R,2S,3R,4R)-2,3-Dihydroxy-4-(hydroxymethyl)-1-aminocyclopentane hydrochloride, 98% ee;(1R,2S,3R,4R)-2,3-Dihydroxy-4-(hydroxymethyl)-1-aminocyclopentane hydrocloride;(1R,2S,3R,4R)-2,3-Dihydroxy-4-(hydroxymethyl)-1-aminocyclopentane hydrochloride,95%,98% ee;(1R,2S,3R,4R)-2,3-Dihydroxy-4-(hydroxymethyl)-1-aminocyclopentaneHCl;(1R,2S,3R,5R)-3-Amino-5-(hydroxymethyl)-cyclopentane-1,2-diol hydrochloride
• CAS NO: 79200-57-0
• Molecular Formula: C₆H₁₃NO₃*ClH
• Molecular Weight: 183.63
• Mol File: 79200-57-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 300.855°C at 760 mmHg
• Flash Point: 135.752°C
• Appearance: /
• Density: 1.2361 (rough estimate)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.5810 (estimate)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: (1R,2S,3R,4R)-2,3-DIHYDROXY-4-(HYDROXYMETHYL)-1-AMINOCYCLOPENTANE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2S,3R,4R)-2,3-DIHYDROXY-4-(HYDROXYMETHYL)-1-AMINOCYCLOPENTANE HYDROCHLORIDE(79200-57-0)
• EPA Substance Registry System: (1R,2S,3R,4R)-2,3-DIHYDROXY-4-(HYDROXYMETHYL)-1-AMINOCYCLOPENTANE HYDROCHLORIDE(79200-57-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26
• Hazardous Substances Data: 79200-57-0(Hazardous Substances Data)

Usage

Chemical Properties

white to off-white crystalline powder and/or

Uses

(1R,2S,3R,5R)-3-Amino-5-(hydroxymethyl)-1,2-cyclopentanediol Hydrochloride is used as a reagent in the synthesis of pyridofuran substituted pyrimidine derivatives as hepatitus C virus (HCV) replication (replicase) inhibitors.

InChI:InChI=1/C6H13NO3/c7-4-1-3(2-8)5(9)6(4)10/h3-6,8-10H,1-2,7H2/p+1/t3-,4-,5-,6+/m1/s1

Upstream product

• 445469-23-8 (1R,2S,3R,4R)-[2,3-bis-(tert-butyldimethylsilanyloxy)-4-hydroxymethyl-cyclopentyl]carbamic acid tert-butyl ester 
• 79200-54-7 methyl (1S,2R,3S,4R)-4-amino-2,3-dihydroxycyclopentane-1-carboxylate hydrochloride 

Downstream Products

• 1379540-62-1 [(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-6-yl]methanol 
• 1379541-20-4 N-{[(3aR,4R,6R,6aS)-6-[4-(cyclopropylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-yl]methyl}-N-{4-[6-chloro-5-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,3-benzodiazol-2-yl]butyl}methanesulfonamide 
• 1379540-60-9 N-[4-(5-tert-butyl-1H-1,3-benzodiazol-2-yl)butyl]-N-{[(1R,2R,3S,4R)-4-[4-(cyclopropylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2,3-dihydroxycyclopentyl]methyl}methanesulfonamide monohydrochloride 
• 1379541-19-1 N-{[(3aR,4R,6R,6aS)-6-[4-(cyclopropylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-yl]methyl}-N-[4-(5-tert-butyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,3-benzodiazol-2-yl)butyl]methanesulfonamide 
• 1379541-18-0 7-[(3aS,4R,6R,6aR)-6-({[4-(5-tert-butyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,3-benzodiazol-2-yl)butyl]amino}methyl)-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-yl]-N-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1379540-45-0 1-(3-((( (1R,2R,3S,4R)-4-(6-amino-9H-purin-9-yl)-2,3-dihydroxycyclopentyl)methyl)(methyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea 
• 1379541-15-7 1-(3-((((3aR,4R,6R,6aS)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)(methyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea 
• 1379541-14-6 2-(3-((((3aR,4R,6R,6aS)-6-(6-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)(methyl)amino)propyl)isoindoline-1,3-dione 
• 1379541-12-4 2-(3-((((3aR,4R,6R,6aS)-6-(6-chloro-9H-purin-9-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)(methyl)amino)propyl)isoindoline-1,3-dione 
• 1379541-10-2 benzyl((3aS,4R,6R,6aR)-6-(((3-(1,3-dioxoisoindolin-2-yl)propyl)(methyl)amino)methyl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)carbamate 
• 1379541-09-9 7-[(3aS,4R,6R,6aR)-6-({[4-(5,6-dichloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,3-benzodiazol-2-yl)butyl](propan-2-yl)amino}methyl)-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-yl]-N-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1379541-08-8 7-[(3aS,4R,6R,6aR)-2,2-dimethyl-6-{[methyl({4-[6-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,3-benzodiazol-2-yl]butyl})amino]methyl}-hexahydrocyclopenta[d][1,3]dioxol-4-yl]-N-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1379541-07-7 7-[(3aS,4R,6R,6aR)-2,2-dimethyl-6-[({4-[6-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,3-benzodiazol-2-yl]butyl}amino)methyl]-hexahydrocyclopenta[d][1,3]dioxol-4-yl]-N-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1379540-42-7 (1R,2S,3R,5R)-3-(4-(cyclopropylamino)-7H-pyrrolo[2,3-d ]pyrimidin-7-yl)-5-((methyl( 4-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)butyl)amino)methyl)cyclopentane-1,2-diol 

Relevant articles and documents

RNAs Containing Carbocyclic Ribonucleotides

Toward the goal of evaluation of carbocyclic ribonucleoside-containing oligonucleotide therapeutics, we developed convenient, scalable syntheses of all four carbocyclic ribonucleotide phosphoramidites and the uridine solid-support building block. Crystall

CARBOCYCLIC NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE

The present invention provides carbocyclic nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such carbocyclic nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the carbocyclic nucleoside compounds of the present invention